Drugs / Baiya SARS-CoV-2 Vax 1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04953078 | Sep → Dec 2021 | Coronaviridae infectious disease | Baiya Phytopharm Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Baiya SARS-CoV-2 Vax 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04953078 ↗ |
| Modality | Vaccine | “RBD-Fc-based Vaccine” NCT04953078 ↗ |
| Route | Intramuscular | “Intramuscular injection in the deltoid region” NCT04953078 ↗ |